Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 143

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 143
---
 losses of KRW 784.6 million and KRW 12.29 billion for years ending 2022 and 2023, respectively, and operating losses of KRW 4.8 billion and 8.8 billion for the six months ending June 30, 2023 and 2024, respectively. We have an accumulated deficit of KRW 21.14 billion as of June 30, 2024. We are likely to continue to incur operating losses in the future. While our RMC subsidiary generated revenues of KRW 4.38 billion and profits of KRW 78.1 million in 2023, and KRW 1.98 billion and KRW 2.42 billion in the six months ending June 30, 2023 and 2024, respectively, none of our other subsidiaries have generated any revenues from product sales because none of their current product candidates have received marketing or other required regulatory approvals anywhere in the world. We may never generate product revenue from the commercial sales of our pharmaceutical product candidates or achieve profitability. Our business is dependent on the success of our product candidates that we advance into clinical trials and ultimately commercial distribution, which will require managing complex scientific, regulatory, management, sales, licensing and other issues. Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: •successfully develop new product candidates through our drug development strategy and advance those product candidates into pre -clinicalstudies and clinical trials; 73 •successfully complete ongoing pre -clinicalstudies and clinical trials and obtain regulatory approvals for our current and future product candidates; •attract and retain experienced management and advisory teams; •add operational, financial and management information systems and personnel, including personnel to support clinical, pre -clinicalmanufacturing and planned future commercialization efforts and operations; •achieve market acceptance of product candidates in the medical community and with third -partypayors and consumers; and •maintain, expand and protect our intellectual property portfolio. If we cannot successfully execute any one of the foregoing, our business may not succeed and the price of our common shares and warrants may be negatively impacted. If one or more of our product candidates encounters safety or efficacy problems, development delays, regulatory issues or other problems, our development plans and business could be significantly harmed. Before we can generate any revenue from sales of any of our product candidates, we must undergo additional preclinical and clinical development, regulatory review and approval in one or more jurisdictions. In addition,